Summary of Study ST002235

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001425. The data can be accessed directly via it's Project DOI: 10.21228/M8HX4C This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002235
Study TitleApplication of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Study SummarySummary: There is a need for biomarkers predictive of response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC). We previously obtained evidence that a polyamine signature in the blood is associated with TNBC development and progression. In this study, we evaluated whether plasma polyamines and other metabolites may identify TNBC patients who are unlikely to respond to NACT. Pre-treatment plasma levels of acetylated polyamines were elevated in TNBC patients that had moderate to extensive tumor burden (RCB-II/III) following NACT compared to those that achieved a complete pathological response (pCR/RCB-0) or had minimal residual disease (RCB-I). We further applied artificial intelligence to comprehensive metabolic profiles to identify additional metabolites associated with treatment response. A deep learning model (DLM) consisting of two polyamines as well as nine additional metabolites was developed for improved prediction of RCB-II/III. The DLM has potential clinical value for identifying TNBC patients who are unlikely to respond to NACT and who may benefit from other treatment modalities.
Institute
University of Texas MD Anderson Cancer Center
Last NameCai
First NameYining
Address6767 Bertner Avenue, Houston, Texas, 77030
Emailycai4@mdanderson.org
Phone713-563-3096
Submit Date2022-05-26
Raw Data AvailableYes
Raw Data File Type(s)raw(Waters)
Analysis Type DetailLC-MS
Release Date2022-08-10
Release Version1
Yining Cai Yining Cai
https://dx.doi.org/10.21228/M8HX4C
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Combined analysis:

Analysis ID AN003645
Analysis type MS
Chromatography type Reversed phase
Chromatography system Waters XEVO-G2XSQTOF
Column C18
MS Type ESI
MS instrument type QTOF
MS instrument name Waters Xevo-G2-XS
Ion Mode POSITIVE
Units ppm

MS:

MS ID:MS003396
Analysis ID:AN003645
Instrument Name:Waters Xevo-G2-XS
Instrument Type:QTOF
MS Type:ESI
MS Comments:Data were processed using Progenesis QI (Non-linear, Waters). Peak picking and retention time alignment of LC-MS and MSe data were performed using Progenesis QI software (Non-linear, Waters)
Ion Mode:POSITIVE
  logo